亚盛医药-B获机构积极评级,股价微跌资金流入

新浪财经
Feb 21

来源:经济观察网经济观察网 根据机构观点整合,2026年2月多家机构对亚盛医药-B(06855.HK)维持积极评级,买入或增持观点占比100%市场观点。中金公司2025年12月研报指出,耐立克(奥雷巴替尼)全球注册III期研究POLARIS-1获美国FDA和欧洲EMA批准开展,利生妥(APG-2575)注册临床数据亮眼,维持目标价89港币。股票近期走势近7日(截至2026年2月20日),亚盛医药-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10